These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33308674)

  • 1. Adverse drug reactions & drug interactions in MDR-TB patients.
    Gupta A; Kumar V; Natarajan S; Singla R
    Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions in tuberculosis and management.
    Prasad R; Singh A; Gupta N
    Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of multidrug-resistant tuberculosis patient's skin drug reaction in Zanzibar: A certain causal relationship with Clofazimine.
    Mohamed SA; Mshana JO; Abubakar K; Juma AH; Mussa IA; Hamad MF; Juma JK; Khalid FJ; Lyakurwa DM
    Int J Mycobacteriol; 2022; 11(1):116-119. PubMed ID: 35295034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study.
    Nilamsari WP; Rizqi MF; Regina NO; Wulaningrum PA; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):783-787. PubMed ID: 34214373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [THE FREQUENCIES AND MANAGEMENT OF ADVERSE REACTIONS IN MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT].
    Sasaki Y; Yoshiyama T; Okumura M; Morimoto K; Miyamoto M; Irina ; Yoshimori K; Kurashima A; Ogata H; Gotoh H
    Kekkaku; 2017 Jan; 92(1):11-19. PubMed ID: 30646468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB.
    Potter JL; Capstick T; Ricketts WM; Whitehead N; Kon OM
    Thorax; 2015 Mar; 70(3):297-8. PubMed ID: 24928813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
    Dela AI; Tank NKD; Singh AP; Piparva KG
    Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.
    Kargar M; Mansouri A; Hadjibabaie M; Javadi M; Radfar M; Gholami K
    Expert Opin Drug Saf; 2014 Jul; 13(7):875-91. PubMed ID: 24935479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.
    Kelly AM; Smith B; Luo Z; Given B; Wehrwein T; Master I; Farley JE
    Int J Tuberc Lung Dis; 2016 Apr; 20(4):442-7. PubMed ID: 26970151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
    Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
    Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.